First clinical trial of a MERS coronavirus DNA vaccine

Yoon, In Kyu; Kim, Jerome H.

doi:10.1016/s1473-3099(19)30397-4

Cited by 17 publications

(14 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the first DNA vaccine candidate against MERS-CoV to enter clinical trials, named GLS-5300, was well tolerated with no vaccine-associated serious adverse events. Immune responses were dose-independent, detected in more than 85% of participants after two immunization regimens, and durable through one year of follow-up [ 41 , 42 ].…”

Section: Sars-cov-2mentioning

confidence: 99%

DNA vaccines against COVID-19: Perspectives and challenges

2021

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) is caused by a novel coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is associated with several fatal cases worldwide. The rapid spread of this pathogen and the increasing number of cases highlight the urgent development of vaccines. Among the technologies available for vaccine development, DNA vaccination is a promising alternative to conventional vaccines. Since its discovery in the 1990s, it has been of great interest because of its ability to elicit both humoral and cellular immune responses while showing relevant advantages regarding producibility, stability, and storage. This review aimed to summarize the current knowledge and advancements on DNA vaccines against COVID-19, particularly those in clinical trials.

show abstract

Section: Sars-cov-2mentioning

confidence: 99%

DNA vaccines against COVID-19: Perspectives and challenges

2021

View full text Add to dashboard Cite

show abstract

“…A closely related virus, SARS-CoV, had caused the illness (severe acute respiratory syndrome or SARS) in 2003 9 ; it has since been studied carefully. Additionally, work had been conducted on developing a vaccine for SARS 10 and for another coronavirus that causes middle-East respiratory syndrome (MERS) 11 , 12 as well as on systems for the rapid development of vaccines against future potential pandemic organisms. 13 …”

Section: Commentarymentioning

confidence: 99%

The UK approach to COVID-19 vaccination: why was it so different?

English¹

2021

DIC

View full text Add to dashboard Cite

The vaccination campaign in the United Kingdom has been extremely successful. Bold decisions were made to order vaccines early, before we knew if they would be effective, and to vary from the manufacturers’ recommendations by extending the ‘prime-boost’ interval between the first and second doses of the AstraZeneca and Pfizer-BioNTech vaccines. These decisions were controversial at the time but have contributed enormously to the effectiveness of the vaccination programme. This is a personal perspective on the approach to COVID-19 vaccination in the United Kingdom.

show abstract

“…DNA vaccines are simple rings of DNA containing a gene encoding a specific vaccine antigen under the regulation of a promotor ( 53 ). DNA vaccine technology has been intensively used to develop vaccines against various pathogens ( 54 , 55 ), cancer ( 56 ), and autoimmune disorders ( 57 ). For example, the human immunodeficiency virus-1 (both as a prophylactic and an immunotherapeutic vaccine) ( 58 , 59 ), Zika virus ( 60 ), and Ebola virus vaccines ( 61 ) are currently in clinical trials.…”

Section: Prospects and Challenges For Anti-sths Vaccine Designmentioning

confidence: 99%

Soil-Transmitted Helminth Vaccines: Are We Getting Closer?

Zawawi

Else

2020

Front. Immunol.

View full text Add to dashboard Cite

Parasitic helminths infect over one-fourth of the human population resulting in significant morbidity, and in some cases, death in endemic countries. Despite mass drug administration (MDA) to school-aged children and other control measures, helminth infections are spreading into new areas. Thus, there is a strong rationale for developing anthelminthic vaccines as cost-effective, long-term immunological control strategies, which, unlike MDA, are not haunted by the threat of emerging drug-resistant helminths nor limited by reinfection risk. Advances in vaccinology, immunology, and immunomics include the development of new tools that improve the safety, immunogenicity, and efficacy of vaccines; and some of these tools have been used in the development of helminth vaccines. The development of anthelminthic vaccines is fraught with difficulty. Multiple lifecycle stages exist each presenting stage-specific antigens. Further, helminth parasites are notorious for their ability to dampen down and regulate host immunity. One of the first significant challenges in developing any vaccine is identifying suitable candidate protective antigens. This review explores our current knowledge in lead antigen identification and reports on recent pre-clinical and clinical trials in the context of the soil-transmitted helminths Trichuris , the hookworms and Ascaris . Ultimately, a multivalent anthelminthic vaccine could become an essential tool for achieving the medium-to long-term goal of controlling, or even eliminating helminth infections.

show abstract

First clinical trial of a MERS coronavirus DNA vaccine

Cited by 17 publications

References 7 publications

DNA vaccines against COVID-19: Perspectives and challenges

DNA vaccines against COVID-19: Perspectives and challenges

The UK approach to COVID-19 vaccination: why was it so different?

Soil-Transmitted Helminth Vaccines: Are We Getting Closer?

Contact Info

Product

Resources

About